PHATHOM PHARMACEUTICALS INC
PHATNASDAQ🏆 #2277 by market capEarnings Oct 28US Equity
$8.51▼ $0.06 (−0.70%)
Market closed · at close1h—
24h▼ 0.7%
7d▲ 3.5%
14d▼ 26.9%
30d▼ 22.1%
1y▼ 17.9%
🏦Market Cap
$679M
Small Cap
📈Revenue Growth (YoY)
+110.2%
High Growth
📊Gross Margin
82.9%
High
💵FCF Margin
—
⚖️P/S Ratio
2.9x
Cheap
Otter Score
42
Weak
Trading Snapshot
- Day Range
- $8.42 – $8.57
- 52-Week Range
- $8.21 – $18.31
- Volume
- $2.13B
- Avg Volume
- $2.40B
- Shares Outstanding
- 79.8M
- Next Earnings
- Sep 20, 2026
Fundamentals Snapshot
- Annual Revenue
- $175M
- Last Q Revenue
- $74M
- P/E Ratio
- —
- P/S Ratio
- 2.9x
- EPS (TTM)
- $-1.27
- Dividend Yield
- —
Why Investors Own PHAT
- ✓High-growth profile — revenue up +46.0% YoY with expanding US Equity exposure.
- ✓Healthy economics — 47% gross margin and 29% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$175M▲ +53.1% YoY
Gross Margin (TTM)
46.5%▲ +0.8% YoY
Operating Income (TTM)
$42M▲ +53.1% YoY
Free Cash Flow (TTM)
$51M▲ +53.1% YoY
About PHATHOM PHARMACEUTICALS INC
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company is headquartered in Florham Park, New Jersey.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
42/100
Analyst Price Target
ⓘAverage Target
$8.81
▲ +3.5% Upside
High Target$9.83
Low Target$7.35
Based on 17 analysts
Latest News & Updates
🚀
MarketWatch·2h ago
PHATHOM PHARMACEUTICALS INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
Barron’s·5h ago
Analysts lift PHAT price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
CNBC·1d ago
PHATHOM PHARMACEUTICALS INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.